TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29661413
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (both atomisation and drops)
Study: 24691606
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of tadalafil daily for 24 weeks
Study: 14711459
Drug: Chicken extract
Normalized name: chicken extract 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken extract (CE) group, 70 mL/bottle, three times a day, providing 18 g protein from the 37th week of pregnancy to 3 days postpartum.
Study: 14711459
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, high protein supplement was restricted.
Study: 10423058
Drug: Successful therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful therapy (omeprazole or fundoplication)
Study: 2160441
Drug: VLCD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLCD with dietary fibre (30 g/day)
Study: 7031568
Drug: Heparin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin prophylaxis (5,000 micro sodium heparin subcutaneously every 12 hours)
Study: 22234648
Drug: Twice-a-week supervised
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-week supervised aerobic and resistance training plus exercise counselling (exercise group)
Study: 20138446
Drug: Iron intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron intake of 1.11 mg/kg/day (SD 0.06)
Study: 7942250
Drug: Tonic water
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonic water administration (placebo)
Study: 24498968
Drug: Enzyme-treated asparagus
Normalized name: Asparagus
DrugBank: Asparagus (DB10503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-treated asparagus extract (ETAS) at 200 mg/kg body weight
Study: 24498968
Drug: Enzyme-treated asparagus
Normalized name: Asparagus
DrugBank: Asparagus (DB10503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-treated asparagus extract (ETAS) at 1000 mg/kg body weight
Study: 24498968
Drug: Enzyme-treated asparagus
Normalized name: Asparagus
DrugBank: Asparagus (DB10503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-treated asparagus extract (ETAS) at 150 mg/d for 7 days
Study: 24498968
Drug: Enzyme-treated asparagus
Normalized name: Asparagus
DrugBank: Asparagus (DB10503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-treated asparagus extract (ETAS) at 0.125 mg/mL
Study: 24498968
Drug: Enzyme-treated asparagus
Normalized name: Asparagus
DrugBank: Asparagus (DB10503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-treated asparagus extract (ETAS) at 1.0 mg/mL
Study: 18090049
Drug: nevirapine 400
Normalized name: nevirapine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nevirapine 400 mg once-daily (n = 31)
Study: 18090049
Drug: nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nevirapine 200 mg twice-a-day (n = 31)
Study: 9923580
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice with 2 mg pranidipine
Study: 9923580
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice with 2 mg pranidipine
Study: 9923580
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with 2 mg pranidipine
Study: 8087824
Drug: Captopril (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50-200 mg daily)
Study: 8087824
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN; 5 and 15 mg)
Study: 8087824
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with captopril and ISDN
Study: 1103563
Drug: Diphenidol (1,1‐diphenyl‐4‐piperidino‐l‐butanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenidol (1,1‐diphenyl‐4‐piperidino‐l‐butanol hydrochloride)
Study: 19519891
Drug: All LTFU
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All LTFU participants in the treatment group had the event; none in the control group (worst case scenario)
Study: 17900783
Drug: Chitosan mouth
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan mouth rinse solution
Study: 10204813
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg controlled‐release nifedipine once daily
Study: 10204813
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sustained‐release nifedipine twice daily
Study: 27974169
Drug: Antibiotics-first treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics-first treatment (intravenous ertapenem for ≥48 hours, followed by oral cefdinir and metronidazole)
Study: 27974169
Drug: Antibiotics-first treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics-first treatment
Study: 24039797
Drug: Complementary food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary food supplements containing multiple vitamins and minerals provided daily for 1.5 years.
Study: 21435103
Drug: Fat infusion
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat infusion (F)
Study: 21435103
Drug: Carbohydrate infusion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate infusion (C)
Study: 21435103
Drug: Protein infusion
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein infusion (P)
Study: 14762367
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 patients with normal platelet counts and no previous extended exposure to heparin)
Study: 9517521
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg three times daily for 12 weeks
Study: 1333617
Drug: Clonidine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (dose not specified)
Study: 23232168
Drug: Epley maneuver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epley maneuver (rehabilitation treatment)
Study: 19139884
Drug: Ipilimumab (anti-CTLA-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (anti-CTLA-4 monoclonal antibody)
Study: 9849693
Drug: G‐CSF starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF starting on day +1
Study: 9849693
Drug: G‐CSF starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF starting on day +7
Study: 7889637
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg sustained release daily)
Study: 7889637
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg sustained release daily)
Study: 209485
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg estradiol valerate (single oral dose)
Study: 29642743
Drug: Weekly problem‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly problem‐based sessions led by psychologists over 3 months
Study: 24115188
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 40 mg/day) plus lovastatin (30 mg/day)
Study: 10955034
Drug: Therapy focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy focusing on reversing the underlying disorder and providing supportive treatment
Study: 9244023
Drug: Paracetamol 325
Normalized name: Paracetamol 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 325 mg/dextropropoxyphene hydrochloride 32.5 mg
Study: 9244023
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg/codeine phosphate 30 mg
Study: 8143995
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with folinic acid 200 mg/m2 plus 5-fluorouracil 400 mg/m2, intravenously, on days 1-5 every 4 weeks for 12 cycles
Study: 29231320
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (carbamazepine)
Study: 23134408
Drug: TAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC with 6 months steroids withdrawal (6M SW)
Study: 23134408
Drug: TAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC with 3 months steroids withdrawal (3M SW)
Study: 23134408
Drug: TAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC with 14 days steroids withdrawal (14d SW)
Study: 23134408
Drug: TAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC with basiliximab induction and steroids avoidance (Bas SA)
Study: 15199653
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and psychoeducation
Study: 15199653
Drug: Medication without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication without psychoeducation
Study: 11300428
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) 400 microg sublingual
Study: 9378379
Drug: Atropine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (15 micrograms/kg intravenous bolus and 4 micrograms/kg/h maintenance dose)
Study: 3535012
Drug: Cisapride 8
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride 8 mg intravenously
Study: 3535012
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg intravenously
Study: 3535012
Drug: Cisapride 1
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 1 mg atropine pretreatment
Study: 3535012
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg three times daily (1-week treatment)
Study: 28921241
Drug: DHEA 6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 6.5 mg
Study: 28921241
Drug: DHEA 3.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 3.25 mg
Study: 28921241
Drug: DHEA 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 6.25 mg
Study: 25013997
Drug: NNC0195‐0092 (0.01‐0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0195‐0092 (0.01‐0.32 mg/kg) single dose
Study: 25013997
Drug: NNC0195‐0092 (0.02‐0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0195‐0092 (0.02‐0.24 mg/kg) once-weekly doses for 4 weeks
Study: 18474811
Drug: Anakinra (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (150 mg s.c.)
Study: 14600860
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% with sufentanil 0.5 microg/ml
Study: 8869862
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (group 1: 0.3 mg.kg‐1 i.v. bolus, 0.12 mg.kg‐1.h‐1 i.v. infusion)
Study: 8869862
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (group 2: 0.5 mg.kg‐1 i.v. bolus, 0.24 mg.kg‐1.h‐1 i.v. infusion)
Study: 8869862
Drug: Heparin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (150 IU.kg‐1 i.v. bolus, 20 IU.kg‐1.h‐1 i.v. infusion)
Study: 26471380
Drug: BRV 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV 100 mg/day
Study: 21386714
Drug: Medication (control)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (control)
Study: 16979857
Drug: Clustered nursing
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clustered nursing care (CC)
Study: 14688156
Drug: 50 IU
Normalized name: Pegaspargase 750 IU/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU of recombinant FSH daily and GnRH antagonist Ganirelix 0.25 mg per day
Study: 14688156
Drug: 50 IU
Normalized name: Pegaspargase 750 IU/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU of recombinant FSH on alternate days and GnRH antagonist Ganirelix 0.25 mg per day
Study: 18206738
Drug: Defibrillator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrillator therapy
Study: 9626173
Drug: Medications alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications alone (Control)
Study: 2835195
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (10 mg)
Study: 28266949
Drug: venlafaxine 75 mg + hypnosis
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine 75 mg + hypnosis (VH)
Study: 28266949
Drug: venlafaxine 75 mg + sham
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine 75 mg + sham hypnosis (VSH)
Study: 28266949
Drug: placebo pill + hypnosis
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill + hypnosis (PH)
Study: 28266949
Drug: placebo pill + sham
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill + sham hypnosis (PSH)
Study: 26245216
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment defined by IFX and anti‐IFX antibodies (n = 33)
Study: 16804124
Drug: Free amino
Normalized name: FREE AMINO ACID DIET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free amino acid solutions
Study: 16804124
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral meal (healthy volunteers)
Study: 14674505
Drug: 24% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% EDTA gel followed by 5% NaOCl for 2 minutes
Study: 14674505
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no etching agent and/or NaOCl solution)
Study: 11009265
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus cilostazol (group II, n = 208, 254 lesions) for 6 months
Study: 11009265
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticlopidine (group I, n = 201, 240 lesions) for 1 month
Study: 11009265
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus cilostazol (group II) in diabetic patients
Study: 11009265
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticlopidine (group I) in diabetic patients
Study: 11009265
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus cilostazol (group II)
Study: 11009265
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticlopidine (group I)
Study: 1581367
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment control group
Study: 6146180
Drug: Diphenhydramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (150 mg)
Study: 25966781
Drug: OZ439 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 plus PQP (800 mg OZ439 with 960 mg PQP)
Study: 25966781
Drug: OZ439 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 plus PQP (800 mg OZ439 with 1440 mg PQP)
Study: 17236636
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target controlled infusion (TCI) with noxious stimulus (hand immersion in cold water at 2-4 degrees C)
Study: 17236636
Drug: Remifentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil TCI infusion added to propofol TCI anesthesia
Study: 12771852
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (2 tablets/day for 6 months)
Study: 12771852
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy alone (Control group)
Study: 8812724
Drug: Chronic sodium
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic sodium benzoate (SB) therapy
Study: 4084669
Drug: Allopurinol tablets
Normalized name: Allopurinol Tablets
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol tablets 100 mg, DAK
Study: 4084669
Drug: Apurin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apurin tablets 100 mg, Gea
Study: 30205427
Drug: Carnosine 2
Normalized name: ASCORBIC ACID 200 mg / Vitamin D 20 ug / FOLIC ACID 1667 ug / CYANOCOBALAMIN 6 ug / CALCIUM CITRATE 40 mg / IRON PROTEIN SUCCINYLATE 3.6 mg / MAGNESIUM GLYCINATE 8.5 mg / MAGNESIUM OXIDE 60.3 mg / ZINC 8 mg / POLAPREZINC 37.5 mg / CARNOSINE 28 mg ORAL CAPSULE [Remedient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine 2 g
Study: 27049809
Drug: 3.0% diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0% diquafosol tetrasodium ophthalmic solution
Study: 24976433
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg as selenomethionine)
Study: 20880348
Drug: Sodium tungstate
Normalized name: Sodium Tungstate Dihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium tungstate (100 mg bid)
Study: 18024853
Drug: GW501516 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW501516 (10 mg o.d.)
Study: 16005162
Drug: Morphine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (50 mg and 25 mg)
Study: 1942422
Drug: Zidovudine 1200
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 1200 mg daily (protocol 016)
Study: 1942422
Drug: Zidovudine 500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 500 mg daily (protocol 019)
Study: 1942422
Drug: Zidovudine 1500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 1500 mg daily (protocol 019)
Study: 1942422
Drug: Zidovudine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (any dosage)
Study: 6791868
Drug: Oral mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mannitol alone
Study: 6791868
Drug: Oral mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mannitol with colonic washout
Study: 31711752
Drug: ABI-H0731 100
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H0731 100 mg
Study: 31711752
Drug: ABI-H0731 200
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H0731 200 mg
Study: 31711752
Drug: ABI-H0731 300
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H0731 300 mg
Study: 31711752
Drug: ABI-H0731 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H0731 (various doses)
Study: 30968678
Drug: Lertal +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lertal + standard treatment
Study: 30968678
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + standard treatment
Study: 28660990
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy (Michigan splint) for 30 days
Study: 19515290
Drug: Daily alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily alcohol use
Study: 23303903
Drug: Ginger (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (2.0 g daily for 28 days)
Study: 16540287
Drug: Ampiroxicam 27
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampiroxicam 27 mg
Study: 7742745
Drug: rhu EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhu EPO (300 units per kg/day given thrice weekly by intravenous injection)
Study: 2285274
Drug: Rimantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine (100 mg daily)
Study: 7433474
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg doxycycline daily for 10 days
Study: 7433474
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg doxycycline on the first day and 100 mg on subsequent days for 8 days
Study: 30707360
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement cycle (HRC)
Study: 30208454
Drug: Piperacillin-tazobactam, 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam, 4.5 g, every 6 hours (n=188 participants)
Study: 30208454
Drug: Meropenem, 1
Normalized name: Meropenem, 1000 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem, 1 g, every 8 hours (n=191 participants)
Study: 22575072
Drug: Low ED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low ED (consume ≥10 foods ≤1.0 kcal/g dietary ED and ≤2 foods ≥3.0 kcal/g dietary ED per day)
Study: 17942381
Drug: Calcium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium therapy
Study: 16291885
Drug: Modafinil (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200-400 mg/day)
Study: 15248189
Drug: Onofin-K (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onofin-K (200 mg)
Study: 15248189
Drug: Nizoral (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizoral (200 mg)
Study: 11317474
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fluvastatin twice per day over a 3-month period (n = 14)
Study: 9393270
Drug: BCAAs (Aminoleban
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAAs (Aminoleban EN) 100 g per day for 1 year
Study: 3583472
Drug: Euphylong administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphylong administered after a hot evening meal
Study: 3583472
Drug: Euphylong administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphylong administered before a cold evening meal